$CBLL

Foehr David sold $224K of CBLL

Foehr David (Senior VP, Finance and PAO) sold 9,255 shares of Ceribell, Inc. (CBLL) at an average of $24.25 ($24.25–$24.26, $0.22M total) across 2 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Foehr David
Published Sep 11, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Bearish
medium confidence
Mentioned
$CBLL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLBearishLow
01

Why it matters

The disclosed sale provides fresh data for short-term traders but is unlikely to move the stock significantly.

02

Market read

Primary insider sale; modest size; limited trading relevance.

03

What to watch

The insider retains a sizable holding of 34,144 shares, indicating continued confidence.

Relevance 3/10Novelty 5/10Timing: transaction dated Sep 8, 2026

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan sale is pre-arranged and may not reflect current sentiment.

Company-level read

Ticker impact

$CBLLBearishMedium confidence
Context

Senior VP of Finance sold 9,255 shares for $224K via a 10b5-1 plan on Sep 8, 2026.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

The sale size is modest relative to float, but insider status and use of a 10b5-1 plan suggest a neutral to slightly negative impact.

Market effects

Minimal impact on the medical device sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Ceribell, Inc.

    Medical device company specializing in neuro-monitoring.

  • David Foehr

    Senior Vice President, Finance and PAO at Ceribell.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor